27,736 Shares in Hims & Hers Health, Inc. (NYSE:HIMS) Bought by Nicholas Wealth LLC.

Nicholas Wealth LLC. purchased a new position in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) in the 1st quarter, according to the company in its most recent filing with the SEC. The fund purchased 27,736 shares of the company's stock, valued at approximately $820,000.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Commonwealth Equity Services LLC increased its stake in shares of Hims & Hers Health by 111.6% in the 4th quarter. Commonwealth Equity Services LLC now owns 58,894 shares of the company's stock valued at $1,424,000 after acquiring an additional 31,062 shares during the last quarter. Natixis Advisors LLC acquired a new position in Hims & Hers Health during the fourth quarter valued at approximately $617,000. Xponance Inc. grew its holdings in Hims & Hers Health by 12.3% during the fourth quarter. Xponance Inc. now owns 14,103 shares of the company's stock valued at $341,000 after purchasing an additional 1,540 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS bought a new stake in Hims & Hers Health in the fourth quarter valued at approximately $987,000. Finally, American Century Companies Inc. raised its holdings in Hims & Hers Health by 8.8% in the fourth quarter. American Century Companies Inc. now owns 140,758 shares of the company's stock worth $3,404,000 after purchasing an additional 11,425 shares during the period. 63.52% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research firms have recently commented on HIMS. Needham & Company LLC reaffirmed a "hold" rating on shares of Hims & Hers Health in a research report on Monday, June 23rd. Morgan Stanley reaffirmed an "equal weight" rating and issued a $40.00 price objective on shares of Hims & Hers Health in a research report on Wednesday, June 11th. Wall Street Zen upgraded Hims & Hers Health from a "hold" rating to a "buy" rating in a report on Sunday, July 20th. Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating on shares of Hims & Hers Health in a report on Wednesday, May 7th. Finally, Bank of America boosted their price objective on shares of Hims & Hers Health from $22.00 to $26.00 and gave the company an "underperform" rating in a research report on Tuesday, April 29th. Three analysts have rated the stock with a sell rating, eight have given a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Hold" and an average target price of $39.83.

Hims & Hers Health Stock Performance

Shares of HIMS traded up $0.18 on Friday, hitting $57.50. 46,302,225 shares of the stock traded hands, compared to its average volume of 30,801,588. The company has a market capitalization of $12.87 billion, a PE ratio of 83.33, a P/E/G ratio of 2.11 and a beta of 2.02. Hims & Hers Health, Inc. has a one year low of $13.47 and a one year high of $72.98. The business has a 50 day simple moving average of $53.15 and a 200 day simple moving average of $42.77.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last posted its quarterly earnings results on Monday, May 5th. The company reported $0.20 earnings per share for the quarter, topping the consensus estimate of $0.12 by $0.08. Hims & Hers Health had a return on equity of 22.75% and a net margin of 9.24%. The firm had revenue of $586.01 million during the quarter, compared to analysts' expectations of $535.21 million. During the same quarter in the previous year, the business earned $0.05 earnings per share. The company's revenue was up 110.7% on a year-over-year basis. On average, equities analysts expect that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Insider Activity at Hims & Hers Health

In other news, CEO Andrew Dudum sold 128,127 shares of the firm's stock in a transaction dated Friday, May 16th. The stock was sold at an average price of $58.40, for a total value of $7,482,616.80. Following the transaction, the chief executive officer owned 89,311 shares of the company's stock, valued at $5,215,762.40. This trade represents a 58.93% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Michael Chi sold 17,102 shares of the company's stock in a transaction that occurred on Tuesday, June 17th. The stock was sold at an average price of $59.75, for a total transaction of $1,021,844.50. Following the completion of the transaction, the insider owned 278,654 shares of the company's stock, valued at approximately $16,649,576.50. The trade was a 5.78% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 788,368 shares of company stock worth $42,410,254 over the last quarter. Company insiders own 13.71% of the company's stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.